Several items pertaining to the postoperative assessment of remission in patients with functioning tumors did not achieve consensus, including early prolactin or growth hormone (GH) measurements in patients with prolactinomas or acromegaly, respectively, and subsequent post-glucose GH testing in acromegaly, or the measurements of plasma adrenocorticotropic hormone, 24-h urinary free cortisol, and late-night salivary cortisol in Cushing’s disease. The gene discussed is GH1; the disease is acromegaly.